HC Wainwright Brokers Reduce Earnings Estimates for CNTX

Context Therapeutics Inc. (NASDAQ:CNTX) – Research analysts at HC Wainwright dropped their Q1 2026 earnings per share (EPS) estimates for Context Therapeutics in a research report issued on Tuesday, March 24th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($0.14) for the quarter, down from their prior forecast of ($0.11). The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Context Therapeutics’ Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.60) EPS, FY2027 earnings at ($0.65) EPS, FY2028 earnings at ($0.63) EPS, FY2029 earnings at ($0.44) EPS and FY2030 earnings at $0.08 EPS.

Context Therapeutics (NASDAQ:CNTX) last issued its earnings results on Monday, March 23rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.04).

Other equities research analysts have also recently issued reports about the stock. D. Boral Capital reissued a “buy” rating and issued a $9.00 price objective on shares of Context Therapeutics in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Context Therapeutics in a research note on Wednesday, January 21st. Piper Sandler boosted their price target on Context Therapeutics from $4.00 to $7.00 and gave the company an “overweight” rating in a report on Tuesday. Guggenheim reiterated a “buy” rating and issued a $5.00 price target on shares of Context Therapeutics in a report on Tuesday. Finally, Wall Street Zen raised Context Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Context Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.60.

Context Therapeutics Price Performance

CNTX stock opened at $2.67 on Thursday. Context Therapeutics has a 12 month low of $0.49 and a 12 month high of $3.62. The firm’s 50-day moving average is $2.44 and its 200 day moving average is $1.61. The company has a market capitalization of $245.32 million, a PE ratio of -7.03 and a beta of 1.96.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CNTX. Blue Owl Capital Holdings LP raised its position in shares of Context Therapeutics by 0.3% in the 4th quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock worth $10,926,000 after acquiring an additional 25,000 shares in the last quarter. Vanguard Group Inc. boosted its position in Context Therapeutics by 4.0% during the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock valued at $3,387,000 after purchasing an additional 134,449 shares in the last quarter. Millennium Management LLC purchased a new position in Context Therapeutics in the fourth quarter valued at about $3,824,000. Marshall Wace LLP grew its stake in Context Therapeutics by 7,153.7% in the fourth quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock valued at $3,812,000 after purchasing an additional 2,557,448 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Context Therapeutics by 58.8% in the fourth quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock worth $747,000 after purchasing an additional 188,202 shares in the last quarter. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Context Therapeutics

Here are the key news stories impacting Context Therapeutics this week:

• Positive Sentiment: Piper Sandler raised its price target from $4.00 to $7.00 and assigned an “overweight” rating, signaling stronger upside expectations. Article Title
• Positive Sentiment: Guggenheim reaffirmed a “buy” rating and maintains a $5.00 price target, supporting additional analyst-driven buying interest. Article Title
• Positive Sentiment: D. Boral Capital reaffirmed a “buy” and set a $9.00 target — the most aggressive upside among recent analysts — which can attract momentum investors. Article Title
• Neutral Sentiment: Context released its full-year 2025 operating and financial results; investors will need to parse the report for cash runway, R&D spending, and guidance to judge longer-term impact. Full-Year 2025 Results
• Neutral Sentiment: Multiple short-interest notices cite a “large increase” but report zero shares and NaN changes — this appears to be a data/reporting glitch rather than confirmed new short positions; treat short-interest signals as unreliable until corrected.
• Negative Sentiment: The company reported a quarterly EPS miss on March 23 (reported -$0.14 vs. consensus -$0.10), which is a headwind for sentiment and may be weighing on the stock despite analyst optimism.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.